糖鎖生物学/グライコバイオロジー市場 : 2027 年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年11月

糖鎖生物学/グライコバイオロジー市場 : 製品 [酵素 (グリコシダーゼ、トランスフェラーゼ)、機器 (質量分析、クロマトグラフィー、アレイ)、キット、炭水化物、試薬]、用途 (創薬、診断)、エンドユーザー – 2027 年までの世界予測
Glycomics/Glycobiology Market by Product (Enzymes (Glycosidases, Transferases), Instruments (Mass Spectrometry, Chromatography, Arrays), Kits, Carbohydrates, Reagents), Application (Drug Discovery, Diagnostics), End User – Global Forecast to 2027

ページ数 307
図表数 417
種別 英文調査報告書
価格

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

The glycomics/glycobiology market is projected to reach USD 3.7 Billion by 2027 from USD 1.8 Billion in 2022, at a CAGR of 15.5% during the forecast period. The growth of the market is projected to be driven by factors such as increasing number of collaboration and partnership by prominent players in the market for improved glycan analysis, emerging use of glycans as biomarker, and technological advancement.

糖鎖生物学/グライコバイオロジー市場 : 製品 [酵素 (グリコシダーゼ、トランスフェラーゼ)、機器 (質量分析、クロマトグラフィー、アレイ)、キット、炭水化物、試薬]、用途 (創薬、診断)、エンドユーザー - 2027 年までの世界予測

The enzyme segment grabbed the highest share of the glycomics/glycobiology market in 2022:

Based on product, the glycomics/glycobiology market is segmented into enzymes, kits, instruments, carbohydrates and reagents & chemicals. In 2022, the highest share of the market is held by enzyme segment. This is owing to the consumable nature of enzymes and wide application in R&D activities.

The drug discovery & development segment accounts for the largest share of the application segment in glycomics/glycobiology market.
In 2021, the drug discovery & development segment accounted for the largest share of the market. The largest share of this segment is due to the increasing application of glycomics in drug discovery and development and rising R&D investment by pharmaceutical & biotechnology.
Major players in the glycomics/glycobiology market are Thermo Fisher Scientific (US), New England Biolabs (US), Merck KGaA (Germany), Promega Corporation (US), Waters Corporation (US), Takara Bio Inc, (Japan), Bio-Techne (US), Agilent Technologies (US), Sumitomo Bakelite Co. Ltd. (Japan), Bruker Corporation (US), Shimadzu Corporation (Japan), Danaher Corporation (US), AMS Bio (UK), Ludger Ltd (UK), Z Biotech, LLC (US), Chemily Glycoscience (US), CD BioGlyco (US), GlycoDiag (France), Kode Biotech Limited (New Zealand), Glyxera GmBH (Germany), Lectenz Bio (US), Glycomix Ltd (UK), IEC Group (Italy), Asparia Glycomics (Spain) and Ray Biotech Life Inc. (US).
“North America: Accounted for the largest share in the glycomics/glycobiology market”
The North America is estimated to be the fastest-growing segment of the market, owing to the increasing presence of pharmaceutical and biotechnology companies, improved healthcare infrastructure and more increasing investments by companies in glycobiology research. In this region, US reports the fastest growth of the glycomics/glycobiology market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side – 20%
• By Designation: Managers- 45%, CXOs and Director level – 30%, and Executives – 25%
• By Region: North America -20%, Europe -15%, Asia-Pacific -55%, RoW -10%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific (US)
• New England Biolabs (US)
• Merck KGaA (Germany)
• Promega Corporation (US)
• Waters Corporation (US)
• Takara Bio Inc, (Japan)
• Bio-Techne (US)
• Agilent Technologies (US)
• Sumitomo Bakelite Co. Ltd. (Japan)
• Bruker Corporation (US)
• Shimadzu Corporation (Japan)
• Danaher Corporation (US)
• AMS Bio (UK)
• Ludger Ltd (UK)
• Z Biotech, LLC (US)
• Chemily Glycoscience (US)
• CD BioGlyco (US)
• GlycoDiag (France)
• Kode Biotech Limited (New Zealand)
• Glyxera GmBH (Germany)
• Lectenz Bio (US)
• Glycomix Ltd (UK)
• IEC Group (Italy)
• Asparia Glycomics (Spain)
• Ray Biotech Life Inc. (US)

Glycomics/Glycobiology Market by Product (Enzymes (Glycosidases, Transferases), Instruments (Mass Spectrometry, Chromatography, Arrays), Kits, Carbohydrates, Reagents), Application (Drug Discovery, Diagnostics), End User - Global Forecast to 2027

Research Coverage:
This report provides a detailed picture of the glycomics/glycobiology market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end users and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall glycomics/glycobiology market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.


目次

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.2.1 INCLUSIONS AND EXCLUSIONS 39
1.3 STUDY SCOPE 40
1.4 YEARS CONSIDERED 40
1.5 CURRENCY CONSIDERED 41
1.6 LIMITATIONS 41
1.7 STAKEHOLDERS 41
1.8 SUMMARY OF CHANGES 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH APPROACH 43
FIGURE 1 RESEARCH DESIGN 43
2.1.1 PRIMARY RESEARCH 44
FIGURE 2 GLYCOMICS/GLYCOBIOLOGY MARKET: PRIMARY RESPONDENTS 44
2.2 MARKET ESTIMATION METHODOLOGY 45
FIGURE 3 GLYCOMICS/GLYCOBIOLOGY MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2021 45
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021 46
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 47
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 47
2.3 MARKET GROWTH RATE PROJECTIONS 48
FIGURE 6 GLYCOMICS/GLYCOBIOLOGY MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS 49
2.4 DATA TRIANGULATION 50
FIGURE 7 DATA TRIANGULATION METHODOLOGY 50
2.5 RESEARCH ASSUMPTIONS 51
2.6 RISK ANALYSIS 51
3 EXECUTIVE SUMMARY 52
FIGURE 8 GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT,
2022 VS. 2027 (USD MILLION) 52
FIGURE 9 GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 53
FIGURE 10 GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 54
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF GLYCOMICS/GLYCOBIOLOGY MARKET 55

4 PREMIUM INSIGHTS 56
4.1 GLYCOMICS/GLYCOBIOLOGY MARKET OVERVIEW 56
FIGURE 12 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 56
4.2 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT
AND COUNTRY (2021) 57
FIGURE 13 ENZYMES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2021 57
4.3 GLYCOMICS/GLYCOBIOLOGY MARKET SHARE, BY PRODUCT, 2022 VS. 2027 58
FIGURE 14 ENZYMES SEGMENT TO DOMINATE MARKET IN 2027 58
4.4 GLYCOMICS/GLYCOBIOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
FIGURE 15 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
FIGURE 16 GLYCOMICS/GLYCOBIOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
TABLE 1 GLYCOMICS/GLYCOBIOLOGY MARKET: IMPACT ANALYSIS 61
5.2.1 DRIVERS 61
5.2.1.1 Emergence of glycans as biomarkers 61
5.2.1.2 Technological advancements in glycan analysis 62
5.2.1.3 Increasing R&D expenditure and funding 62
FIGURE 17 R&D EXPENDITURE BY PHRMA MEMBER COMPANIES,
2001–2021 (USD BILLION) 62
TABLE 2 FUNDING FOR NIH INNOVATION PROJECTS UNDER 21ST CENTURY CURES ACT, 2017–2026 63
5.2.1.4 Collaborations and partnerships 64
5.2.1.5 Increasing number of cancer cases worldwide 64
FIGURE 18 NUMBER OF NEW CASES WORLDWIDE, 2020 64
5.2.2 RESTRAINTS 65
5.2.2.1 High cost of glycobiology products and tools 65
5.2.3 OPPORTUNITIES 65
5.2.3.1 Glycomics applications in precision medicine 65
5.2.4 CHALLENGES 65
5.2.4.1 Lack of skilled workforce 65
5.3 RANGES/SCENARIOS 66
FIGURE 19 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF GLYCOMICS/GLYCOBIOLOGY MARKET 66
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 67
FIGURE 20 REVENUE SHIFT AND NEW REVENUE POCKETS 67
5.5 PRICING ANALYSIS 67
TABLE 3 AVERAGE SELLING PRICES OF PRODUCTS OFFERED BY KEY PLAYERS 67
5.6 TECHNOLOGY ANALYSIS 69
5.6.1 CELL-FREE SYNTHETIC GLYCOBIOLOGY 69
5.6.2 GLYCAN MICROARRAY PLATFORMS 69
5.6.3 MASS SPECTROMETRY FOR GLYCOSAMINOGLYCANS 69
5.7 VALUE CHAIN ANALYSIS 69
FIGURE 21 VALUE CHAIN ANALYSIS OF GLYCOMICS/GLYCOBIOLOGY MARKET 70
5.8 ECOSYSTEM ANALYSIS 71
FIGURE 22 ECOSYSTEM ANALYSIS: GLYCOMICS/GLYCOBIOLOGY MARKET 71
TABLE 4 SUPPLY CHAIN ECOSYSTEM 71
5.9 KEY CONFERENCES AND EVENTS IN 2022–2023 72
TABLE 5 GLYCOMICS/GLYCOBIOLOGY MARKET: LIST OF CONFERENCES AND EVENTS 72
5.10 REGULATORY ANALYSIS 72
5.10.1 NORTH AMERICA 72
5.10.2 EUROPE 72
5.10.3 EMERGING MARKETS 73
5.11 PORTER’S FIVE FORCES ANALYSIS 73
TABLE 6 GLYCOMICS/GLYCOBIOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 73
5.11.1 THREAT OF NEW ENTRANTS 73
5.11.2 THREAT OF SUBSTITUTES 73
5.11.3 BARGAINING POWER OF BUYERS 73
5.11.4 BARGAINING POWER OF SUPPLIERS 74
5.11.5 DEGREE OF COMPETITION 74
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 74
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON PHARMACEUTICAL AND
BIOTECHNOLOGY COMPANIES IN BUYING PROCESS OF GLYCOMICS/GLYCOBIOLOGY PRODUCTS 74
FIGURE 24 BUYING CRITERIA FOR GLYCOMICS/GLYCOBIOLOGY PRODUCTS 74
6 GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT 75
6.1 INTRODUCTION 76
TABLE 7 GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 76
6.2 ENZYMES 76
TABLE 8 ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION) 76
TABLE 9 NORTH AMERICA: ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 10 EUROPE: ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 11 ASIA PACIFIC: ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 12 LATIN AMERICA: ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 13 ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 79
6.2.1 GLYCOSIDASES 79
6.2.1.1 Glycosidases to hold largest share of enzymes market 79
TABLE 14 GLYCOSIDASES MARKET, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 15 NORTH AMERICA: GLYCOSIDASES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 80
TABLE 16 EUROPE: GLYCOSIDASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 17 ASIA PACIFIC: GLYCOSIDASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 18 LATIN AMERICA: GLYCOSIDASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.2.2 TRANSFERASES 81
6.2.2.1 Transferase catalyzes transfer of specific functional groups 81
TABLE 19 TRANSFERASES MARKET, BY REGION, 2020–2027 (USD MILLION) 82
TABLE 20 NORTH AMERICA: TRANSFERASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 21 EUROPE: TRANSFERASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 22 ASIA PACIFIC: TRANSFERASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 23 LATIN AMERICA: TRANSFERASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84
6.2.3 OTHER ENZYMES 84
TABLE 24 OTHER ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION) 84
TABLE 25 NORTH AMERICA: OTHER ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 26 EUROPE: OTHER ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 27 ASIA PACIFIC: OTHER ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 28 LATIN AMERICA: OTHER ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
6.3 KITS 86
TABLE 29 KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 87
TABLE 30 NORTH AMERICA: KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 31 EUROPE: KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 32 ASIA PACIFIC: KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 33 LATIN AMERICA: KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 34 KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 89
6.3.1 GLYCAN RELEASING KITS 89
6.3.1.1 Separation of glycans from glycoproteins is the foremost step in glycomics 89
TABLE 35 GLYCAN RELEASING KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 36 NORTH AMERICA: GLYCAN RELEASING KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 37 EUROPE: GLYCAN RELEASING KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 38 ASIA PACIFIC: GLYCAN RELEASING KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 39 LATIN AMERICA: GLYCAN RELEASING KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
6.3.2 GLYCAN LABELING KITS 92
6.3.2.1 Advancements in labeling kits to drive market growth 92
TABLE 40 GLYCAN LABELING KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 92
TABLE 41 NORTH AMERICA: GLYCAN LABELING KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 42 EUROPE: GLYCAN LABELING KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 43 ASIA PACIFIC: GLYCAN LABELING KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 44 LATIN AMERICA: GLYCAN LABELING KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94
6.3.3 GLYCAN PURIFICATION KITS 95
6.3.3.1 Need to separate unwanted material from samples for better characterization to drive use of purification kits 95
TABLE 45 GLYCAN PURIFICATION KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 46 NORTH AMERICA: GLYCAN PURIFICATION KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 47 EUROPE: GLYCAN PURIFICATION KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 48 ASIA PACIFIC: GLYCAN PURIFICATION KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 49 LATIN AMERICA: GLYCAN PURIFICATION KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 97
6.3.4 OTHER KITS 97
TABLE 50 OTHER KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 97
TABLE 51 NORTH AMERICA: OTHER KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 52 EUROPE: OTHER KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 53 ASIA PACIFIC: OTHER KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 54 LATIN AMERICA: OTHER KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 99
6.4 REAGENTS & CHEMICALS 100
6.4.1 GROWING DEMAND FOR REAGENTS & CHEMICALS TO DRIVE MARKET GROWTH 100
TABLE 55 REAGENTS & CHEMICALS MARKET, BY REGION, 2020–2027 (USD MILLION) 100
TABLE 56 NORTH AMERICA: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 57 EUROPE: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 58 ASIA PACIFIC: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 59 LATIN AMERICA: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 102
6.5 CARBOHYDRATES 102
TABLE 60 CARBOHYDRATES MARKET, BY REGION, 2020–2027 (USD MILLION) 102
TABLE 61 NORTH AMERICA: CARBOHYDRATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 62 EUROPE: CARBOHYDRATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 63 ASIA PACIFIC: CARBOHYDRATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 64 LATIN AMERICA: CARBOHYDRATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 65 CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 105
6.5.1 OLIGOSACCHARIDES 105
6.5.1.1 Oligosaccharides to dominate carbohydrates segment 105
TABLE 66 OLIGOSACCHARIDES MARKET, BY REGION, 2020–2027 (USD MILLION) 105
TABLE 67 NORTH AMERICA: OLIGOSACCHARIDES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 68 EUROPE: OLIGOSACCHARIDES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 69 ASIA PACIFIC: OLIGOSACCHARIDES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 107
TABLE 70 LATIN AMERICA: OLIGOSACCHARIDES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 107
6.5.2 MONOSACCHARIDES 108
6.5.2.1 Growing use in solution/buffer preparation to drive market 108
TABLE 71 MONOSACCHARIDES MARKET, BY REGION, 2020–2027 (USD MILLION) 108
TABLE 72 NORTH AMERICA: MONOSACCHARIDES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 73 EUROPE: MONOSACCHARIDES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 74 ASIA PACIFIC: MONOSACCHARIDES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 75 LATIN AMERICA: MONOSACCHARIDES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 110
6.5.3 OTHER CARBOHYDRATES 110
TABLE 76 OTHER CARBOHYDRATES MARKET, BY REGION, 2020–2027 (USD MILLION) 110
TABLE 77 NORTH AMERICA: OTHER CARBOHYDRATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 78 EUROPE: OTHER CARBOHYDRATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 79 ASIA PACIFIC: OTHER CARBOHYDRATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 80 LATIN AMERICA: OTHER CARBOHYDRATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 112
6.6 INSTRUMENTS 112
TABLE 81 INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 113
TABLE 82 NORTH AMERICA: INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 113
TABLE 83 EUROPE: INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 84 ASIA PACIFIC: INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 85 LATIN AMERICA: INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 86 INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
6.6.1 MASS SPECTROMETRY INSTRUMENTS 115
6.6.1.1 Wide use of mass spectrometry in glycan analysis to support segment growth 115
TABLE 87 MASS SPECTROMETRY INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 116
TABLE 88 NORTH AMERICA: MASS SPECTROMETRY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 116
TABLE 89 EUROPE: MASS SPECTROMETRY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 90 ASIA PACIFIC: MASS SPECTROMETRY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 91 LATIN AMERICA: MASS SPECTROMETRY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 118
6.6.2 CHROMATOGRAPHY INSTRUMENTS 118
6.6.2.1 Need to separate unwanted material during glycan analysis to drive demand for chromatography instruments 118
TABLE 92 CHROMATOGRAPHY INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 119
TABLE 93 NORTH AMERICA: CHROMATOGRAPHY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 119
TABLE 94 EUROPE: CHROMATOGRAPHY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 95 ASIA PACIFIC: CHROMATOGRAPHY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 96 LATIN AMERICA: CHROMATOGRAPHY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 121
6.6.3 ARRAYS 121
6.6.3.1 Increasing demand for glycan, lectin, and antibody arrays to drive market growth 121
TABLE 97 ARRAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 121
TABLE 98 NORTH AMERICA: ARRAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 122
TABLE 99 EUROPE: ARRAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 122
TABLE 100 ASIA PACIFIC: ARRAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 101 LATIN AMERICA: ARRAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
6.6.4 OTHER INSTRUMENTS 124
TABLE 102 OTHER INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 124
TABLE 103 NORTH AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 104 EUROPE: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 105 ASIA PACIFIC: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 106 LATIN AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
7 GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION 127
7.1 INTRODUCTION 128
TABLE 107 GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
7.2 DRUG DISCOVERY & DEVELOPMENT 128
7.2.1 INCREASING IMPORTANCE OF GLYCAN ANALYSIS IN DRUG DEVELOPMENT TO DRIVE GROWTH 128
TABLE 108 GLYCOMICS/GLYCOBIOLOGY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION) 129
TABLE 109 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 110 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 111 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 112 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 131
7.3 DIAGNOSTICS 131
TABLE 113 GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 132
TABLE 114 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 132
TABLE 115 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 133
TABLE 116 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 133
TABLE 117 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 134
TABLE 118 GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 134
7.3.1 CANCER DIAGNOSTICS 134
7.3.1.1 Rising importance of glycomics in cancer diagnostics to support market growth 134
TABLE 119 GLYCOMICS/GLYCOBIOLOGY MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 135
TABLE 120 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 121 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 122 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 123 LATIN AMERICA GLYCOMICS/GLYCOBIOLOGY MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 137
7.3.2 OTHER DIAGNOSTIC APPLICATIONS 137
TABLE 124 GLYCOMICS/GLYCOBIOLOGY MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 137
TABLE 125 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 126 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 127 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 139
TABLE 128 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 139
7.4 OTHER APPLICATIONS 139
TABLE 129 GLYCOMICS/GLYCOBIOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 140
TABLE 130 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 131 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 132 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 133 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 142
8 GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER 143
8.1 INTRODUCTION 144
TABLE 134 GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 144
8.2 ACADEMIC & RESEARCH INSTITUTES 144
8.2.1 ACADEMIC & RESEARCH INSTITUTES TO ACCOUNT FOR LARGEST MARKET SHARE 144
TABLE 135 GLYCOMICS/GLYCOBIOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 145
TABLE 136 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 145
TABLE 137 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 146
TABLE 138 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 146
TABLE 139 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 147
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 147
8.3.1 INCREASING INTEREST IN DEVELOPING CARBOHYDRATE-BASED THERAPEUTICS TO DRIVE SEGMENT GROWTH 147
TABLE 140 GLYCOMICS/GLYCOBIOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 147
TABLE 141 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 148
TABLE 142 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 148
TABLE 143 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 149
TABLE 144 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 149
8.4 CLINICAL LABORATORIES 149
8.4.1 RISING BURDEN OF INFECTIOUS DISEASE AND CANCER TO DRIVE MARKET GROWTH 149
TABLE 145 GLYCOMICS/GLYCOBIOLOGY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 150
TABLE 146 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 147 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 151
TABLE 148 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 151
TABLE 149 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 152
8.5 CONTRACT RESEARCH ORGANIZATIONS 152
8.5.1 RISING PREFERENCE FOR OUTSOURCING TO DRIVE MARKET GROWTH 152
TABLE 150 GLYCOMICS/GLYCOBIOLOGY MARKET FOR CROS, BY REGION, 2020–2027 (USD MILLION) 152
TABLE 151 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR CROS, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 152 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR CROS, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 153 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET FOR CROS, BY COUNTRY, 2020–2027 (USD MILLION) 154
TABLE 154 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR CROS, BY COUNTRY, 2020–2027 (USD MILLION) 154
9 GLYCOMICS/GLYCOBIOLOGY MARKET, BY REGION 155
9.1 INTRODUCTION 156
TABLE 155 GLYCOMICS/GLYCOBIOLOGY MARKET, BY REGION, 2020–2027 (USD MILLION) 156
9.2 NORTH AMERICA 157
FIGURE 25 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET SNAPSHOT 157
TABLE 156 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158
TABLE 157 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 158
TABLE 158 NORTH AMERICA: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 159 NORTH AMERICA: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 160 NORTH AMERICA: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 161 NORTH AMERICA: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 160
TABLE 162 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 160
TABLE 163 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 164 NORTH AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 161
9.2.1 US 162
9.2.1.1 US to hold largest share of glycomics/glycobiology market 162
TABLE 165 US: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 162
TABLE 166 US: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 163
TABLE 167 US: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 163
TABLE 168 US: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 163
TABLE 169 US: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 164
TABLE 170 US: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 164
TABLE 171 US: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 164
TABLE 172 US: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 165
9.2.2 CANADA 165
9.2.2.1 Increasing government funding and strong infrastructure to drive growth 165
TABLE 173 CANADA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 166
TABLE 174 CANADA: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 175 CANADA: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 167
TABLE 176 CANADA: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 167
TABLE 177 CANADA: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 178 CANADA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 179 CANADA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 180 CANADA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 169
9.3 EUROPE 170
TABLE 181 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 170
TABLE 182 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 170
TABLE 183 EUROPE: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 184 EUROPE: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 185 EUROPE: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 186 EUROPE: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 187 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 188 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 173
TABLE 189 EUROPE: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 173
9.3.1 GERMANY 173
9.3.1.1 Germany to dominate European glycomics/glycobiology market 173
TABLE 190 GERMANY: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 174
TABLE 191 GERMANY: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 192 GERMANY: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 175
TABLE 193 GERMANY: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 175
TABLE 194 GERMANY: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 195 GERMANY: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 176
TABLE 196 GERMANY: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 177
TABLE 197 GERMANY: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 177
9.3.2 UK 177
9.3.2.1 Rising investments in pharmaceutical R&D to boost market growth 177
TABLE 198 UK: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 178
TABLE 199 UK: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 200 UK: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 201 UK: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 202 UK: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 203 UK: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 180
TABLE 204 UK: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 205 UK: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 181
9.3.3 FRANCE 181
9.3.3.1 Well-established life sciences industry to support market growth 181
TABLE 206 FRANCE: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 182
TABLE 207 FRANCE: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 208 FRANCE: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 209 FRANCE: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 210 FRANCE: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 184
TABLE 211 FRANCE: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 184
TABLE 212 FRANCE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 185
TABLE 213 FRANCE: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 185
9.3.4 ITALY 185
9.3.4.1 Increased funding and strong research base to drive market 185
TABLE 214 ITALY: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 186
TABLE 215 ITALY: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 216 ITALY: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 217 ITALY: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 218 ITALY: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 188
TABLE 219 ITALY: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 188
TABLE 220 ITALY: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 221 ITALY: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 189
9.3.5 SPAIN 189
9.3.5.1 Government initiatives to expand pharma & biotech sector to support market growth 189
TABLE 222 SPAIN: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 190
TABLE 223 SPAIN: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 190
TABLE 224 SPAIN: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 191
TABLE 225 SPAIN: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 191
TABLE 226 SPAIN: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 227 SPAIN: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 192
TABLE 228 SPAIN: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 229 SPAIN: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 193
9.3.6 REST OF EUROPE 193
TABLE 230 ROE: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 194
TABLE 231 ROE: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 232 ROE: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 233 ROE: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 234 ROE: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 235 ROE: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 196
TABLE 236 ROE: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 237 ROE: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 196

9.4 ASIA PACIFIC 197
FIGURE 26 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET SNAPSHOT 197
TABLE 238 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 198
TABLE 239 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 198
TABLE 240 ASIA PACIFIC: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 241 ASIA PACIFIC: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 242 ASIA PACIFIC: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 243 ASIA PACIFIC: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 200
TABLE 244 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 200
TABLE 245 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 201
TABLE 246 ASIA PACIFIC: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 201
9.4.1 CHINA 202
9.4.1.1 China to hold largest share of APAC market 202
TABLE 247 CHINA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 202
TABLE 248 CHINA: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 249 CHINA: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 203
TABLE 250 CHINA: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 203
TABLE 251 CHINA: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 204
TABLE 252 CHINA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 204
TABLE 253 CHINA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 205
TABLE 254 CHINA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 205
9.4.2 JAPAN 205
9.4.2.1 Research initiatives for precision medicine to boost market 205
TABLE 255 JAPAN: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 206
TABLE 256 JAPAN: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 257 JAPAN: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 258 JAPAN: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 259 JAPAN: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 260 JAPAN: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 208
TABLE 261 JAPAN: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 209
TABLE 262 JAPAN: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 209
9.4.3 INDIA 209
9.4.3.1 Increased R&D activities to drive market growth 209
TABLE 263 INDIA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 210
TABLE 264 INDIA: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 210
TABLE 265 INDIA: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 266 INDIA: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 267 INDIA: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 212
TABLE 268 INDIA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 212
TABLE 269 INDIA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 270 INDIA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 213
9.4.4 AUSTRALIA 214
9.4.4.1 Rising funding for research to support market growth 214
TABLE 271 AUSTRALIA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 214
TABLE 272 AUSTRALIA: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 214
TABLE 273 AUSTRALIA: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 215
TABLE 274 AUSTRALIA: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 215
TABLE 275 AUSTRALIA: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 276 AUSTRALIA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 216
TABLE 277 AUSTRALIA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 278 AUSTRALIA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 217
9.4.5 REST OF ASIA PACIFIC 217
TABLE 279 ROAPAC: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 218
TABLE 280 ROAPAC: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 281 ROAPAC: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 219
TABLE 282 ROAPAC: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 219
TABLE 283 ROAPAC: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 220
TABLE 284 ROAPAC: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 220
TABLE 285 ROAPAC: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 221
TABLE 286 ROAPAC: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 221
9.5 LATIN AMERICA 221
TABLE 287 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 222
TABLE 288 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 222
TABLE 289 LATIN AMERICA: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 223
TABLE 290 LATIN AMERICA: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 223
TABLE 291 LATIN AMERICA: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 223
TABLE 292 LATIN AMERICA: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 224
TABLE 293 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 224
TABLE 294 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 225
TABLE 295 LATIN AMERICA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 225
9.5.1 BRAZIL 225
9.5.1.1 Brazil to hold largest share of Latin American market 225
TABLE 296 BRAZIL: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 226
TABLE 297 BRAZIL: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 226
TABLE 298 BRAZIL: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 227
TABLE 299 BRAZIL: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 227
TABLE 300 BRAZIL: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 301 BRAZIL: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 228
TABLE 302 BRAZIL: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 303 BRAZIL: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 229
9.5.2 MEXICO 229
9.5.2.1 Well-built pharmaceutical industry to support market growth 229
TABLE 304 MEXICO: CANCER CASES, BY CANCER TYPE, 2020 229
TABLE 305 MEXICO: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 230
TABLE 306 MEXICO: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 307 MEXICO: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 231
TABLE 308 MEXICO: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 231
TABLE 309 MEXICO: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 232
TABLE 310 MEXICO: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 232
TABLE 311 MEXICO: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 312 MEXICO: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 233
9.5.3 REST OF LATIN AMERICA 234
TABLE 313 ROLATAM: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 234
TABLE 314 ROLATAM: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 315 ROLATAM: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 235
TABLE 316 ROLATAM: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 235
TABLE 317 ROLATAM: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 318 ROLATAM: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 236
TABLE 319 ROLATAM: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 237
TABLE 320 ROLATAM: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 237
9.6 MIDDLE EAST & AFRICA 237
9.6.1 INCREASED FOCUS ON PRECISION MEDICINE AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH 237
TABLE 321 MEA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 238
TABLE 322 MEA: ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 238
TABLE 323 MEA: KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 324 MEA: CARBOHYDRATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 325 MEA: INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 240
TABLE 326 MEA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 240
TABLE 327 MEA: GLYCOMICS/GLYCOBIOLOGY MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 241
TABLE 328 MEA: GLYCOMICS/GLYCOBIOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 241
10 COMPETITIVE LANDSCAPE 242
10.1 INTRODUCTION 242
10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 242
FIGURE 27 GLYCOMICS/GLYCOBIOLOGY MARKET: STRATEGIES ADOPTED 243
10.3 MARKET SHARE ANALYSIS 244
FIGURE 28 GLYCOMICS/GLYCOBIOLOGY MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 244
TABLE 329 GLYCOMICS/GLYCOBIOLOGY MARKET: DEGREE OF COMPETITION 244
10.4 REVENUE ANALYSIS 245
FIGURE 29 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021) 245
10.5 COMPANY EVALUATION QUADRANT 246
10.5.1 STARS 246
10.5.2 EMERGING LEADERS 246
10.5.3 PERVASIVE PLAYERS 246
10.5.4 PARTICIPANTS 246
FIGURE 30 GLYCOMICS/GLYCOBIOLOGY MARKET: COMPANY EVALUATION MATRIX, 2022 247
10.6 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES 247
10.6.1 PROGRESSIVE COMPANIES 247
10.6.2 STARTING BLOCKS 247
10.6.3 RESPONSIVE COMPANIES 248
10.6.4 DYNAMIC COMPANIES 248
FIGURE 31 GLYCOMICS/GLYCOBIOLOGY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021 248
10.7 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 249
10.7.1 OVERALL COMPANY FOOTPRINT (25 COMPANIES) 249
TABLE 330 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 249
10.7.2 COMPANY PRODUCT FOOTPRINT (25 COMPANIES) 250
TABLE 331 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS 250
10.7.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES) 251
TABLE 332 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 251
10.7.4 COMPETITIVE BENCHMARKING OF START-UPS/SMES 252
TABLE 333 GLYCOMICS/GLYCOBIOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES 252
TABLE 334 GLYCOMICS/GLYCOBIOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES) 253
10.8 COMPETITIVE SCENARIO AND TRENDS 253
10.8.1 PRODUCT LAUNCHES 253
TABLE 335 GLYCOMICS/GLYCOBIOLOGY MARKET: PRODUCT LAUNCHES, JANUARY 2019–SEPTEMBER 2022 253
10.8.2 DEALS 254
TABLE 336 GLYCOMICS/GLYCOBIOLOGY MARKET: DEALS, JANUARY 2019–SEPTEMBER 2022 254
10.8.3 OTHER DEVELOPMENTS 255
TABLE 337 GLYCOMICS/GLYCOBIOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2019– SEPTEMBER 2022 255
11 COMPANY PROFILES 256
11.1 KEY PLAYERS 256
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 MERCK KGAA 256
TABLE 338 MERCK KGAA: BUSINESS OVERVIEW 256
FIGURE 32 MERCK KGAA: COMPANY SNAPSHOT 257
TABLE 339 MERCK KGAA: PRODUCT OFFERINGS 258
11.1.2 THERMO FISHER SCIENTIFIC 260
TABLE 340 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 260
FIGURE 33 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021) 261
TABLE 341 THERMO FISHER SCIENTIFIC: PRODUCT OFFERINGS 261
11.1.3 AGILENT TECHNOLOGIES 264
TABLE 342 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW 264
FIGURE 34 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT 265
TABLE 343 AGILENT TECHNOLOGIES: PRODUCT OFFERINGS 265
11.1.4 WATERS CORPORATION 269
TABLE 344 WATERS CORPORATION: BUSINESS OVERVIEW 269
FIGURE 35 WATERS CORPORATION: COMPANY SNAPSHOT 270
TABLE 345 WATERS CORPORATION: PRODUCT OFFERINGS 270
11.1.5 NEW ENGLAND BIOLABS 273
TABLE 346 NEW ENGLAND BIOLABS: BUSINESS OVERVIEW 273
11.1.6 TAKARA BIO 275
TABLE 347 TAKARA BIO: BUSINESS OVERVIEW 275
FIGURE 36 TAKARA BIO: COMPANY SNAPSHOT 276
TABLE 348 TAKARA BIO: PRODUCT OFFERINGS 277
11.1.7 SHIMADZU CORPORATION 278
TABLE 349 SHIMADZU CORPORATION: BUSINESS OVERVIEW 278
FIGURE 37 SHIMADZU CORPORATION: COMPANY SNAPSHOT 279
TABLE 350 SHIMADZU CORPORATION: PRODUCT OFFERINGS 279
11.1.8 DANAHER CORPORATION 281
TABLE 351 DANAHER CORPORATION: BUSINESS OVERVIEW 281
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT 282
TABLE 352 DANAHER CORPORATION: PRODUCT OFFERINGS 282
11.1.9 BIO-TECHNE 284
TABLE 353 BIO-TECHNE: BUSINESS OVERVIEW 284
FIGURE 39 BIO-TECHNE: COMPANY SNAPSHOT 285
TABLE 354 BIO-TECHNE: PRODUCT OFFERINGS 285
11.1.10 SUMITOMO BAKELITE 287
TABLE 355 SUMITOMO BAKELITE: BUSINESS OVERVIEW 287
FIGURE 40 SUMITOMO BAKELITE: COMPANY SNAPSHOT 288
TABLE 356 SUMITOMO BAKELITE: PRODUCT OFFERINGS 288
11.1.11 BRUKER CORPORATION 289
TABLE 357 BRUKER CORPORATION: BUSINESS OVERVIEW 289
FIGURE 41 BRUKER CORPORATION: COMPANY SNAPSHOT 290
TABLE 358 BRUKER CORPORATION: PRODUCT OFFERINGS 290
11.1.12 LUDGER 293
TABLE 359 LUDGER: BUSINESS OVERVIEW 293
TABLE 360 LUDGER: PRODUCT OFFERINGS 293
11.1.13 PROMEGA CORPORATION 296
TABLE 361 PROMEGA CORPORATION: BUSINESS OVERVIEW 296
TABLE 362 PROMEGA CORPORATION: PRODUCT OFFERINGS 296
11.1.14 AMSBIO 298
TABLE 363 AMSBIO: BUSINESS OVERVIEW 298
TABLE 364 AMSBIO: PRODUCT OFFERINGS 298
11.1.15 CD BIOGLYCO 300
TABLE 365 CD BIOGLYCO: BUSINESS OVERVIEW 300
TABLE 366 CD BIOGLYCO: PRODUCT OFFERINGS 300
11.1.16 ICE S.P.A. 302
TABLE 367 ICE S.P.A.: BUSINESS OVERVIEW 302
TABLE 368 ICE S.P.A.: PRODUCT OFFERINGS 303
11.1.17 ASPARIA GLYCOMICS 304
TABLE 369 ASPARIA GLYCOMICS: BUSINESS OVERVIEW 304
TABLE 370 ASPARIA GLYCOMICS: PRODUCT OFFERINGS 305
11.1.18 LECTENZ BIO 306
TABLE 371 LECTENZ BIO: BUSINESS OVERVIEW 306
TABLE 372 LECTENZ BIO: PRODUCT OFFERINGS 306
11.1.19 Z BIOTECH, LLC 307
TABLE 373 Z BIOTECH, LLC: BUSINESS OVERVIEW 307
TABLE 374 Z BIOTECH, LLC: PRODUCT OFFERINGS 307
11.1.20 CHEMILY GLYCOSCIENCE 308
TABLE 375 CHEMILY GLYCOSCIENCE: BUSINESS OVERVIEW 308
TABLE 376 CHEMILY GLYCOSCIENCE: PRODUCT OFFERINGS 308
11.2 OTHER COMPANIES 310
11.2.1 GLYCOMIX 310
11.2.2 GLYCODIAG 311
11.2.3 KODE BIOTECH LIMITED 311
11.2.4 GLYXERA GMBH 312
11.2.5 RAYBIOTECH LIFE 312
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 313
12.1 DISCUSSION GUIDE 313
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 316
12.3 CUSTOMIZATION OPTIONS 318
12.4 RELATED REPORTS 318
12.5 AUTHOR DETAILS 319


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com